Angiosarcoma successfully treated with liver transplantation and sirolimus

Area of Science:

• Pediatric oncology
• Hepatobiliary surgery
• Translational medicine

Background:

• Malignant liver tumors are rare in children, accounting for about 1% of pediatric malignancies.
• Hepatic angiosarcoma (HA) is an exceptionally rare, high-grade endothelial tumor with poor prognosis in children.
• Current treatments like chemotherapy, radiation, and resection offer limited efficacy, leading to near-universal recurrence and high mortality after liver transplant (LT).

Observation:

• A pediatric patient with hepatic angiosarcoma presented with a rare and aggressive liver tumor.
• The patient's tumor showed limited response to conventional therapies.
• This case represents the first reported instance of successful treatment for pediatric HA.

Findings:

• The successful treatment involved a combination of pediatric liver transplant (LT) and sirolimus.
• Sirolimus targets the mTOR pathway, crucial for cell proliferation, differentiation, and migration.
• This combined approach demonstrated efficacy in managing a previously intractable pediatric liver cancer.

Implications:

• This case highlights the potential of sirolimus, an mTOR inhibitor, as an anti-neoplastic agent for solid tumors.
• The combination of LT and sirolimus may offer a viable therapeutic strategy for pediatric hepatic angiosarcoma.
• Further research into mTOR pathway inhibition could lead to improved outcomes for children with rare and aggressive liver cancers.